$PVSP 95% of revenue from Artizen’s brands has come from
$PVSP 95% of revenue from Artizen’s brands has come from sales of cannabis flower, supporting its position of the 9th most sold independent flower brand in North America; acquisitions and partnerships will open access to concentrates and edible verticals representing 40% of market sales and heretofore not covered by Artizen products
Artizen projects it will generate $50 million in annualized revenues nationally by end of Q4 2024; this is a conservative estimate that does not include any potential revenue multiples from acquisition of retail opportunities.
24 Months plan detail
Rename Pervasip Corp to Artizen Corporation by year end 2022 to better reflect the new focus of the company
Change the OTC ticker symbol
Re-brand all Pervasip/Artizen assets
Continue to rationalize the business through Q1 2023 with a focus on operating margins, shedding underperforming assets, consolidating operations and focus in-house talent on higher margin operations and product lines
Acquire concentrates assets by end of 2022, launching into the highly lucrative concentrates business
Expand flower and concentrates offerings within our brands as well as adding new brands for certain product offerings and price points through Q1 2023
Complete the audit and begin the OTC QB application process during Q2 2023
Launch Artizen Wellness Q2 2023
Enter the edibles market in Q2 2023 via acquisition and partnerships
Artizen becomes an MSO with cultivation and retail assets in 1 – 2 additional states during 2nd half of 2024, beginning its state expansion in Q1 2023, initially through brand licensing opportunities and strategic partnerships, and eventually via acquisitions and mergers during Q3 and Q4 2024
Close first brand licensing agreement by end of Q4 2022
Close one brand licensing deal every quarter thereafter
Financial Outlook Q3 2022 through Q4 2023
Reach $2.0 million in monthly revenue by end of Q1 2023
Reach $2.5 million or $30 million in annualized revenue by end of Q4 2023 with 30% in adjusted EBIDTA
Reach $3.0 million or $36 million in annualized revenues by end of Q2 2024 with 35% in adjusted EBIDTA
Reach $50 million in annualized revenue with 35% in adjusted EBIDTA
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...
Continue Reading
A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...
Continue Reading
Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...
Continue Reading
Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...
Continue Reading
Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...
Continue Reading
Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...
Continue Reading
Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...
Continue Reading
Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...
Continue Reading
Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Top 5 Most Recently Viewed Articles
A New Chapter in Pharmacy Care Alright, folks, CVS Health just threw its cowboy hat into the ring with a grand opening of its first pharmacy-focused spot down in south Houston. This ain't your typical retail maze—it's a compact little number designed to form tighter bonds between patient and pharmacist, and it's opening the doors to a shift in pharmacy care access. The...
Continue Reading
New Exploration Permit Approved for Rokmaster Resources Rokmaster Resources Corp. (TSXV: RKR) is thrilled to announce the recent approval of a three-year exploration permit critical for their operations on the Fox-Coconut Property. This milestone marks an important step in the company's strategic plan, enabling them to embark on expansive exploration activities aimed at...
Continue Reading
Gleim Aviation Showcases Innovative Training Solutions Gleim Aviation, known for its leadership in aviation education, is excited to unveil cutting-edge training technologies at EAA AirVenture Oshkosh, making waves in the aviation community. Visit Us at Hangar A, Booth 1104 From July 21 to July 27, Gleim Aviation invites flight training professionals, pilots, and aviation...
Continue Reading
Lennox Expands Its HVAC Offerings with New Acquisition Lennox, a prominent name in energy-efficient climate control solutions, has taken a significant step by acquiring the HVAC Division of NSI Industries. This notable acquisition includes the respected Duro Dyne and Supco brands, a move designed to enhance Lennox’s parts and supplies portfolio, offering better services...
Continue Reading
Quantum BioPharma Announces Private Placement Initiative Quantum BioPharma Ltd. (NASDAQ: QNTM) has embarked on a new phase of capital acquisition through a non-brokered private placement. This strategic move will involve issuing class A multiple voting shares (MVS) priced at $50 each, targeting an impressive total of $600 million in gross proceeds aimed at bolstering the...
Continue Reading